Last reviewed · How we verify
NCT00168519
Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes
NA trial testing nitroprusside, pentalong, imdur, AICAR, isoptin in Diabetes Mellitus, Type 2 in 40 participants. Completed in 1 April 2009.
Quick facts
| Lead sponsor | Baker Heart Research Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 October 2002 |
| Estimated completion | 1 April 2009 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- nitroprusside, pentalong, imdur, AICAR, isoptin — full drug profile →
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Baker Heart Research Institute
Who can join
Adults 18 to 65, male only, with Diabetes Mellitus, Type 2. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
glucose metabolism
Time frame: 3 hours
Sponsor's own description
The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cellular bioenergetics as a target for obesity therapy.
Tseng YH, Cypess AM, Kahn CR. · · 2010 · cited 443× · PMID 20514071 · DOI 10.1038/nrd3138 -
PGC1s and Beyond: Disentangling the Complex Regulation of Mitochondrial and Cellular Metabolism.
Coppi L, Ligorio S, Mitro N, Caruso D, et al · · 2021 · cited 31× · PMID 34199142 · DOI 10.3390/ijms22136913
Verify or expand the search:
- PubMed search for NCT00168519
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00168519 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baker Heart Research Institute
- Last refreshed: 14 December 2009
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00168519.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing